Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes
Bone marrow (BM) is a reliable source of multipotent mesenchymal stromal cells (MSCs), which have been successfully used for treating osteonecrosis. Considering the functional advantages of BM-MSCs as bone and cartilage reparatory cells and supporting angiogenesis, several donor-related factors are...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/8/5/69 |
| _version_ | 1797533839272181760 |
|---|---|
| author | Jehan J El-Jawhari Payal Ganguly Elena Jones Peter V Giannoudis |
| author_facet | Jehan J El-Jawhari Payal Ganguly Elena Jones Peter V Giannoudis |
| author_sort | Jehan J El-Jawhari |
| collection | DOAJ |
| description | Bone marrow (BM) is a reliable source of multipotent mesenchymal stromal cells (MSCs), which have been successfully used for treating osteonecrosis. Considering the functional advantages of BM-MSCs as bone and cartilage reparatory cells and supporting angiogenesis, several donor-related factors are also essential to consider when autologous BM-MSCs are used for such regenerative therapies. Aging is one of several factors contributing to the donor-related variability and found to be associated with a reduction of BM-MSC numbers. However, even within the same age group, other factors affecting MSC quantity and function remain incompletely understood. For patients with osteonecrosis, several underlying factors have been linked to the decrease of the proliferation of BM-MSCs as well as the impairment of their differentiation, migration, angiogenesis-support and immunoregulatory functions. This review discusses the quality and quantity of BM-MSCs in relation to the etiological conditions of osteonecrosis such as sickle cell disease, Gaucher disease, alcohol, corticosteroids, Systemic Lupus Erythematosus, diabetes, chronic renal disease and chemotherapy. A clear understanding of the regenerative potential of BM-MSCs is essential to optimize the cellular therapy of osteonecrosis and other bone damage conditions. |
| first_indexed | 2024-03-10T11:20:20Z |
| format | Article |
| id | doaj.art-be759f192ef44e659c9f233ed8490c57 |
| institution | Directory Open Access Journal |
| issn | 2306-5354 |
| language | English |
| last_indexed | 2024-03-10T11:20:20Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj.art-be759f192ef44e659c9f233ed8490c572023-11-21T20:04:52ZengMDPI AGBioengineering2306-53542021-05-01856910.3390/bioengineering8050069Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying CausesJehan J El-Jawhari0Payal Ganguly1Elena Jones2Peter V Giannoudis3Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UKLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, UKLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, UKLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, UKBone marrow (BM) is a reliable source of multipotent mesenchymal stromal cells (MSCs), which have been successfully used for treating osteonecrosis. Considering the functional advantages of BM-MSCs as bone and cartilage reparatory cells and supporting angiogenesis, several donor-related factors are also essential to consider when autologous BM-MSCs are used for such regenerative therapies. Aging is one of several factors contributing to the donor-related variability and found to be associated with a reduction of BM-MSC numbers. However, even within the same age group, other factors affecting MSC quantity and function remain incompletely understood. For patients with osteonecrosis, several underlying factors have been linked to the decrease of the proliferation of BM-MSCs as well as the impairment of their differentiation, migration, angiogenesis-support and immunoregulatory functions. This review discusses the quality and quantity of BM-MSCs in relation to the etiological conditions of osteonecrosis such as sickle cell disease, Gaucher disease, alcohol, corticosteroids, Systemic Lupus Erythematosus, diabetes, chronic renal disease and chemotherapy. A clear understanding of the regenerative potential of BM-MSCs is essential to optimize the cellular therapy of osteonecrosis and other bone damage conditions.https://www.mdpi.com/2306-5354/8/5/69multipotent mesenchymal stromal cellsosteonecrosisautologous bone marrowregenerative therapy |
| spellingShingle | Jehan J El-Jawhari Payal Ganguly Elena Jones Peter V Giannoudis Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes Bioengineering multipotent mesenchymal stromal cells osteonecrosis autologous bone marrow regenerative therapy |
| title | Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes |
| title_full | Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes |
| title_fullStr | Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes |
| title_full_unstemmed | Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes |
| title_short | Bone Marrow Multipotent Mesenchymal Stromal Cells as Autologous Therapy for Osteonecrosis: Effects of Age and Underlying Causes |
| title_sort | bone marrow multipotent mesenchymal stromal cells as autologous therapy for osteonecrosis effects of age and underlying causes |
| topic | multipotent mesenchymal stromal cells osteonecrosis autologous bone marrow regenerative therapy |
| url | https://www.mdpi.com/2306-5354/8/5/69 |
| work_keys_str_mv | AT jehanjeljawhari bonemarrowmultipotentmesenchymalstromalcellsasautologoustherapyforosteonecrosiseffectsofageandunderlyingcauses AT payalganguly bonemarrowmultipotentmesenchymalstromalcellsasautologoustherapyforosteonecrosiseffectsofageandunderlyingcauses AT elenajones bonemarrowmultipotentmesenchymalstromalcellsasautologoustherapyforosteonecrosiseffectsofageandunderlyingcauses AT petervgiannoudis bonemarrowmultipotentmesenchymalstromalcellsasautologoustherapyforosteonecrosiseffectsofageandunderlyingcauses |